J Appl Biomed 9:173-183, 2011 | DOI: 10.2478/v10136-011-0013-4

Neurodegenerative diseases and neuroprotection: current views and prospects

André Nieoullon*
Institut de Biologie du Développement de Marseille-Luminy (IBDML) CNRS, Aix-Marseille Université, Marseille, France

Most of the pathophysiological processes of neurodegenerative diseases share the aggregation of related proteins which is one of the hallmarks of the degenerative processes. Recent advances in the knowledge of these proteinopathies show that the same protein could contribute to a number of diseases, thus suggesting a common pathological process. If this is so, specific instances of the brain neuronal system targeted by protein dysfunction could be a sign of a differential clinical expression rather than different pathological processes. This very stimulating view of the neurodegenerative diseases based on physiopathology has led us to suggest that possible degenerative mechanisms may be shared by different diseases although the causes of the disease itself still remain unclear. Since genetic forms of the degenerative diseases are rather rare, exploring the involvement of genes is one current way of researching the degenerative process of the disease. It is has thus been speculated that idiopathic forms of the diseases are related to close interactions between genetic and environmental factors; the genetic component being able to favour - or perhaps, to protect against - the disease process. Because of the current view that the basic mechanism of cell death in degenerative diseases is related to a rather limited number of processes in which oxidative stress could play a central role resulting in protein dysfunction and aggregation, one can speculate that there are neuroprotective medicines soon to be proposed based on the active limitation of protein accumulation in the brain.

Keywords: neurodegenerative diseases; proteinopathies; Alzheimer's disease; Parkinson's disease; oxidative stress; proteasome; neuroprotection

Received: July 20, 2011; Revised: August 16, 2011; Published: July 31, 2011  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Nieoullon A. Neurodegenerative diseases and neuroprotection: current views and prospects. J Appl Biomed. 2011;9(4):173-183. doi: 10.2478/v10136-011-0013-4.
Download citation

References

  1. Abou-Sleiman PM, Hanna MG, Wood NW. Genetic association studies of complex neurological diseases. J Neurol Neurosurg Psychiat. 77: 1302-1304, 2006. Go to original source... Go to PubMed...
  2. Akwa Y, Allain H, Bentue-Ferrer D, Berr C, Bordet R, Geerts H, Nieoullon A, Onteniente B, Vercelletto M. Neuroprotection and neurodegenerative diseases: from biology to clinical practice. Alzheimer Dis Assoc Disord. 19: 226-239, 2005. Go to original source... Go to PubMed...
  3. Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J. Costs of disorders of the brain in Europe. Eur J Neurol. 12 (Suppl. 1): 1-27, 2005. Go to original source... Go to PubMed...
  4. Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem. 90: 379-391, 2004. Go to original source... Go to PubMed...
  5. Barlow BK, Cory-Slechta DA, Richfield EK, Thiruchelvam M. The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod Toxicol. 23: 457-470, 2007. Go to original source... Go to PubMed...
  6. Barsukova AG, Bourdette D, Forte M. Mitochondrial calcium and its regulation in neurodegeneration induced by oxidative stress. Eur J Neurosci. 10: 437-447, 2011. Go to original source... Go to PubMed...
  7. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature Rev Drug Discovery. 10: 29-46, 2011. Go to original source... Go to PubMed...
  8. Berger Z, Davies JE, Luo S, Pasco MY, Majoul I, O'Kane CJ, Rubinsztein DC. Deleterious and protective properties of an aggregate-prone protein with a polyalanine expansion. Hum Mol Genet. 15: 453-465, 2006. Go to original source... Go to PubMed...
  9. Berger Z, Smith KA, Lavole MJ. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry. 49: 5511-5523, 2010. Go to original source... Go to PubMed...
  10. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson's disease. J Clin Invest. 119: 182-192, 2009. Go to original source...
  11. Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci. 30: 475-483, 2009. Go to original source... Go to PubMed...
  12. Citron M. Strategies for disease modification in Alzheimer's disease. Nature Rev Neurosci. 5: 677-685, 2004. Go to original source... Go to PubMed...
  13. Corti O, Fournier M, Brice A. Neurodegeneration in Parkinson's disease: Genetics enlightens physiopathology. J Neural Transm Suppl. 73: 215-221, 2009. Go to original source... Go to PubMed...
  14. Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A. GDNF fails to exert neuroprotection in a rat (alpha)-synuclein model of Parkinson's disease. Brain. 134: 2302-2311, 2011. Go to original source... Go to PubMed...
  15. Derkinderen P. Classification of neurodegenerative diseases: things are getting complicated (in French). La Lettre du Neurologue. 13: 68, 2009.
  16. Dick FD. Parkinson's disease and pesticide exposures. Br Med Bull. 79-80: 219-231, 2006. Go to original source... Go to PubMed...
  17. Djaldetti R, Lev N, Melamed E. Neuroprotection in progressive brain disorders. Isr Med Assoc J. 5: 576-580, 2003. Go to PubMed...
  18. Friedman DB, Johnson TE. A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics. 118: 75-86, 1988. Go to original source... Go to PubMed...
  19. Gianaros PJ, Jennings JR, Sheu LK, Greer PJ, Kuller LH, Matthews KA. Prospective reports of chronic life stress predict decreased grey matter volume in the hippocampus. Neuroimage. 35: 795-803, 2007. Go to original source... Go to PubMed...
  20. Hampel H, Franck R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H et al. Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nature Rev Drug Discov. 9: 560-574, 2010. Go to original source... Go to PubMed...
  21. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8: 382-397, 2009. Go to original source... Go to PubMed...
  22. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 97: 2892-2897, 2000. Go to original source... Go to PubMed...
  23. Hunter RL, Bing G. Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Curr Neuropharmacol. 5: 35-46, 2007. Go to original source... Go to PubMed...
  24. Josephs KA. Frontotemporal dementia and related disorders: Deciphering the enigma. Ann Neurol. 64: 4-14, 2008. Go to original source... Go to PubMed...
  25. Kristian T, Balan I, Schuh R, Onken M. Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell death and promising targets for neuroprotection. J Neurosci Res. 10: 1002-1016, 2011. Go to original source... Go to PubMed...
  26. Labrande C, Velly L, Canolle B, Guillet B, Masmejean F, Nieoullon A, Pisano P. Neuroprotecive effects of tacrolimus (FK506) in a model of ischemic cortical cell cultures: Role of glutamate uptake and FK506 binding protein 12 kDa. Neuroscience. 137: 231-239, 2006. Go to original source... Go to PubMed...
  27. Llorente R, Gallardo ML, Berzal AL, Prada C, Garcia-Segura LM, Viveros MP. Early maternal deprivation in rats induces gender-dependent effects on developing hippocampal and cerebellar cells. Int J Dev Neurosci. 27: 233-241, 2009. Go to original source... Go to PubMed...
  28. Mabandla MV, Russell VA. Voluntary exercise reduces the neurotoxic effects of 6-hydroxydopamine in maternally separated rats. Behav Brain Res. 211: 16-22, 2010. Go to original source... Go to PubMed...
  29. Marais L, Van Rensburg SJ, Van Zyl JM, Stein DJ, Daniels WMU. Maternal separation of rat pups increases the risk of developing depressive-like behavior after subsequent chronic stress by altering corticosterone and neurotrophin levels in the hippocampus. Neurosci Res. 61: 106-112, 2008. Go to original source... Go to PubMed...
  30. Meilandt WJ, Cisse M, Ho K, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 18: 1977-1986, 2009. Go to original source... Go to PubMed...
  31. Moisan F, Spinosi J, Dupupet JL, Delabre L, Mazurie JL, Goldberg M, Imbernon E, Tzourio C, Elbaz A. The relation between type of farming and prevalence of Parkinson's disease agricultural workers in five French districts. Mov Disord. 26: 271-279, 2011. Go to original source... Go to PubMed...
  32. Nagahara AH, Tuszynski MH. Potential uses of BDNF in neurological and psychiatric disorders. Nature Rev Drug Discov. 10: 209-219, 2011. Go to original source... Go to PubMed...
  33. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL et al. Ubiquinated TDP-43 in fronto-temporal lobar degeneration and amyotrophic lateral sclerosis. Science. 314: 130-133, 2006. Go to original source... Go to PubMed...
  34. Nieoullon A. Alzheimer's disease: neurobiological advances supporting proposals for new therapeutical approaches. J Appl Biomed. 2: 123-130, 2004. Go to original source...
  35. Ozawa T, Healy DG, Abou-Sleiman PM, Ahmadi KR, Quinn N, Lees AJ, Shaw K, Wullner U, Berciano J, Moller JC, Kamm C, Burk K et al. The α-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry. 77: 464-467, 2006. Go to original source... Go to PubMed...
  36. Reglodi D, Kiss P, Lubics A, Tamas A. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des. 17: 962-972, 2011. Go to original source... Go to PubMed...
  37. Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E. Cerebrolysin decreases amyloid-β production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res. 15: 1252-1261, 2006. Go to original source... Go to PubMed...
  38. Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis. 23: 307-318, 2011. Go to original source... Go to PubMed...
  39. Sleegers K, Cruts M, Van Broeckhoven C. Molecular pathways of frontotemporal degeneration. Ann Rev Neurosci. 33: 71-88, 2010. Go to original source... Go to PubMed...
  40. Spivey JM, Shumake J, Colorado RA, Conejo-Jimenez N, Gonzales-Pardo H, Gonzales-Lima F. Adolescent female rats are more resistant than males to the effects of early stress on the prefrontal cortex and impulsive behavior. Dev Psychobiol. 51: 277-288, 2009. Go to original source... Go to PubMed...
  41. Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)α and ERβ ligand treatment. Proc Natl Acad Sci USA. 104: 14813-14818, 2007. Go to original source... Go to PubMed...
  42. Vajda FJ. Neuroprotection and neurodegenerative disease. J Clin Neurosci. 9: 4-8, 2002. Go to original source... Go to PubMed...
  43. Velly L, Guillet B, Masmejean F, Nieoullon A, Bruder N, Gouin FM, Pisano P. Neuroprotective effects of propofol in a model of ischemia cortical cell cultures. Role of glutamate and its transporters. Anesthesiology. 99: 368-375, 2003. Go to original source... Go to PubMed...